baldwin wisconsin help drug-pricing healthcare insulin biosimilars fair-drug-pricing-act ira medicare
related: _Tammy Baldwin Master Profile · PhRMA · Eli Lilly · AbbVie · Blue Cross Blue Shield Association
donors: Blue Cross Blue Shield Association · SEIU
The Drug Pricing Populist
Baldwin has been one of the Senate’s most consistent advocates for prescription drug price reduction across a career spanning more than two decades. Her HELP Committee seat gives her jurisdiction over pharmaceutical regulation, biosimilar approval pathways, and drug pricing policy — the same committee that oversees the industry contributing millions to her campaigns. The record is one of genuine legislative effort operating within structural limits that protect the insurer and hospital sector donors while targeting the pharmaceutical sector where populist pressure is highest and donor-class friction lowest.
The central mechanism: HELP Committee membership creates a formal institutional relationship between Baldwin and the health sector. Healthcare PACs and employees have contributed $5,042,399 to Baldwin’s career (1997–2024) — the fourth-largest sector in her fundraising architecture. But that figure disaggregates critically: Health Professionals (physicians, hospital systems) account for $3.1M career; pharmaceuticals/health products are a small fraction. Baldwin’s drug pricing advocacy targets the pharmaceutical subsector, leaving the insurance and hospital donor base that dominates her health sector fundraising largely untouched.
The FAIR Drug Pricing Act — Transparency Without Price Controls
The Fair Accountability and Innovative Research (FAIR) Drug Pricing Act is Baldwin’s signature pharmaceutical legislation. First introduced in 2017 with Sen. John McCain (R-AZ) and Rep. Jan Schakowsky (D-IL), the bill has been reintroduced in 2019 (with Sen. Mike Braun), 2021 (with Braun, Sen. Tina Smith, Sen. Lisa Murkowski), and passed the HELP Committee in May 2023 under Chairman Bernie Sanders.
What the bill does: it requires drug manufacturers to notify HHS and submit a transparency report before increasing the price of any drug by more than 10 percent in one year or 25 percent over three years. Manufacturers must disclose manufacturing costs, R&D investment, net profits attributable to the drug, and marketing expenditures. HHS publishes the reports publicly within 30 days.
What the bill does not do: it does not cap prices, prohibit increases, or require manufacturers to justify prices already in place. Manufacturers retain full discretion to raise prices — they simply must disclose first.
Contradiction
Baldwin has introduced the FAIR Drug Pricing Act in four separate Congresses (2017, 2019, 2021, 2023). It passed the HELP Committee in May 2023 — the most progress it has made in six years of introduction — and never came to a full Senate floor vote. A transparency bill that requires disclosure but prohibits nothing is the structural ideal for pharmaceutical-adjacent HELP Committee fundraising: it generates populist press releases, shows constituent action, creates pharmaceutical industry friction (which polls well), and never threatens the actual pricing model. The legislation that keeps failing is the legislation that doesn’t cap prices.
The Insulin Fight — Real Win, Structural Limit
Insulin pricing is where Baldwin’s drug pricing advocacy has produced the clearest real-world outcomes and the clearest structural limits simultaneously.
The IRA insulin cap (2022): Baldwin voted for the Inflation Reduction Act in August 2022, which included a $35/month cap on insulin for Medicare Part D beneficiaries. The cap took effect January 1, 2023. This is a genuine policy win: Wisconsin Medicare beneficiaries paying $200-400/month for insulin received direct, immediate relief.
What didn’t pass: The Senate attempted to include a $35 insulin cap for private insurance in the IRA as well. That provision was stripped by the Senate Parliamentarian under the Byrd rule — reconciliation can’t regulate private insurance pricing. Fifty Democrats voted to include it; 57 senators total supported it. It failed on procedural grounds, not vote count. Approximately 7.4 million Americans with private insurance who use insulin did not receive the cap.
The INSULIN Act (2023): Baldwin co-sponsored the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, a bipartisan bill that would have extended the $35 cap to private insurance and removed barriers to insulin access. The bill did not pass. The failure to extend the insulin cap beyond Medicare to private insurance is the structural limit made concrete: the Medicare win was real; the private insurance win, which would have required confronting insurer business models, was not achieved.
The February 2024 HELP Committee Hearing
On February 8, 2024, HELP Committee Chairman Sanders convened a hearing titled “Why Does the United States Pay, By Far, The Highest Prices In The World For Prescription Drugs?” — the most high-profile pharmaceutical CEO confrontation of the 118th Congress. All Democratic members signed the invitation, including Baldwin. The CEOs of Johnson & Johnson (Joaquin Duato), Merck (Robert Davis), and Bristol Myers Squibb (Chris Boerner) testified after Sanders threatened to issue subpoenas when Duato and Davis initially declined.
Baldwin’s questioning focused on two lines of attack: Wisconsin constituent stories of patients rationing medication versus CEO compensation ($25–52.5 million annually for the three executives); and her FAIR Drug Pricing Act, which she pressed as the committee’s institutional response. She called the pharmaceutical executives’ finger-pointing at pharmacy benefit managers “just trying to shed the blame.”
Money
The February 2024 hearing is instructive for what it didn’t produce. Three pharmaceutical CEOs testified before the full HELP Committee, refused to commit to lowering drug prices to match what other countries pay, and left. No binding legislation followed the hearing. The FAIR Drug Pricing Act, which passed committee in May 2023, remained on the floor calendar. The structural function of HELP Committee pharmaceutical hearings: they generate constituent-facing populist positioning, establish HELP members’ “fighting” brand, and produce no prices legislation that threatens actual pharmaceutical pricing power. Baldwin’s questioning of the CEOs is real political pressure. The absence of follow-through legislation is the structural tell.
The Healthcare Donor Architecture
Baldwin’s health sector fundraising illuminates the internal logic of her selective pharmaceutical populism.
Career health sector (1997–2024): $5,042,399 total — $4,065,040 from individuals, $977,359 from PACs. Health Professionals (physicians, medical group employees, hospital system employees) account for the dominant share of the individual total. Pharmaceuticals/health products — the sector Baldwin most aggressively targets — represent a fraction of the overall health total.
2024 cycle health sector: $2,543,795 — the sector Baldwin campaigns on drug pricing reform is contributing more in a single cycle than any previous cycle in her Senate career. Health sector contributions grew from $1.5M (2018 cycle) to $2.54M (2024 cycle) as her drug pricing profile rose.
What the breakdown reveals: Baldwin’s health sector contributions are dominated by Health Professionals ($1,509,232 in 2024 cycle), Health Services/HMOs ($319,265 in 2024 cycle), and insurance companies ($448,007 in 2024 cycle). These represent hospital systems, physician groups, and health insurers — the sectors that benefit from lower pharmaceutical input prices. When Baldwin fights pharmaceutical companies to lower drug prices, she is fighting for lower input costs for the insurers and hospital systems that fund her campaigns. Her drug pricing populism is not simply anti-corporate — it is structurally aligned with the healthcare sector donor base that benefits from pharmaceutical cost reduction.
PhRMA and pharmaceutical companies have spent $30+ million annually lobbying against drug pricing legislation. Baldwin’s advocacy creates friction with PhRMA while her insurer and health professional donor base quietly endorses the direction. The two-audience contradiction operates differently here: Baldwin appears to challenge healthcare industry power while her healthcare donors — specifically the non-pharmaceutical sectors — benefit from the challenge.
Timeline
| Date | Event | Key Players | Amount | Significance |
|---|---|---|---|---|
| 2017 | FAIR Drug Pricing Act first introduced | Baldwin, Sen. John McCain, Rep. Schakowsky | — | First Baldwin pharma transparency bill; requires manufacturers to justify price increases >10%/yr. No price controls — disclosure only. Sets the pattern for six years of reintroduction. |
| Aug 2022 | Inflation Reduction Act passes — Baldwin votes yes | Baldwin, Senate Democrats, President Biden | $369B (total IRA) | IRA authorizes Medicare drug price negotiation for first time in history; $35/month insulin cap for Medicare Part D; pharmaceutical industry spends $100M+ lobbying against it |
| Jan 2023 | Medicare $35 insulin cap takes effect | CMS, Medicare Part D beneficiaries | $35/month cap | Real relief for Wisconsin Medicare insulin users. Private insurance patients uncovered — the structural limit of reconciliation-process drug pricing reform. |
| May 2023 | FAIR Drug Pricing Act passes HELP Committee | Baldwin, Sanders (Chair), bipartisan members | — | Most legislative progress in six-year history of the bill. Never brought to full Senate floor vote. Transparency without price controls advances; price controls remain off the table. |
| Aug 2023 | HHS selects first 10 Part D drugs for Medicare price negotiation | HHS Secretary Becerra, CMS, 10 manufacturers | — | First use of IRA Medicare negotiation authority. Eliquis, Jardiance, Xarelto, Januvia among the 10. All manufacturers agree to participate. Prices effective Jan 2026. |
| 2023 | INSULIN Act introduced — Baldwin co-sponsors | Baldwin, Sen. Collins (R-ME), bipartisan group | — | Would extend $35 insulin cap to private insurance. Does not pass. The failure to extend cap beyond Medicare is the defining structural limit: Medicare wins, private insurance patients remain exposed. |
| Feb 8, 2024 | HELP Committee hearing on pharmaceutical CEO compensation | Sanders (Chair), Baldwin, J&J/Merck/BMS CEOs | CEO pay: $25–52.5M/yr | Baldwin grills CEOs on Wisconsin constituent stories vs. executive compensation. Presses FAIR Drug Pricing Act. CEOs refuse to commit to price reductions. No floor legislation follows. |
| Aug 2024 | CMS announces negotiated prices for 10 drugs | CMS, HHS | 38–79% discounts off list price | IRA negotiation produces real results: projected $6B in Medicare savings if 2023 prices applied. Prices take effect Jan 2026. $1.5B in estimated patient savings. |
| 2024 cycle | Health sector total to Baldwin campaign | Pharma/health products, insurers, health professionals | $2,543,795 | Baldwin’s largest health sector fundraising cycle coincides with her most visible drug pricing advocacy. The populist pressure and the contributor relationships coexist without contradiction in her donor architecture. |
Money
The structural tell is the timeline itself. The FAIR Drug Pricing Act has been introduced in four Congresses (2017, 2019, 2021, 2023). It passed the HELP Committee in May 2023. It never came to a Senate floor vote. The insulin cap for Medicare (IRA, 2022) is real policy. The insulin cap for private insurance (INSULIN Act, 2023) didn’t pass. The pattern: Medicare-administered wins are achievable because they reduce government expenditure and don’t threaten insurer business models. Private insurance wins that would actually cap what insurers charge don’t advance. Baldwin’s drug pricing populism operates in exactly the space her donor architecture allows: against pharmaceutical companies (who don’t dominate her contributor base) and within the structural limits that protect the insurer and hospital sector donors who do.
Class Analysis
Baldwin’s drug pricing record is the clearest example of Genuine Win + Structural Limit in her legislative portfolio. The IRA insulin cap is real — Wisconsin Medicare patients got $35/month insulin. The FAIR Drug Pricing Act generated six years of press releases and one committee passage. The INSULIN Act for private insurance didn’t advance. The Medicare drug price negotiation was a structural breakthrough (first in history) but limited to Medicare Part D.
The structural function served: Baldwin’s drug pricing advocacy reduces pharmaceutical input costs for the insurer and hospital sector donors who fund her campaigns, while generating populist credibility that she challenges the healthcare establishment. She is simultaneously fighting one healthcare sector subsector (pharmaceuticals) and protecting the donor relationships with the other healthcare sector subsectors (insurers, hospital systems, health professionals) who benefit from that fight.
The HELP Committee jurisdiction is not incidental to this analysis — it is the mechanism. Committee members receive healthcare sector contributions for access and influence. Baldwin’s pharmaceutical populism is the form that influence takes when the pharmaceutical sector donor overlap is small and the insurer/hospital donor overlap is large. She fights the sector that doesn’t fund her in order to protect the relationships with the sectors that do.
Sources
- OpenSecrets: Tammy Baldwin career industries (Tier 1)
- OpenSecrets: Tammy Baldwin 2024 cycle industries (Tier 1)
- OpenSecrets: Pharmaceuticals/Health Products sector recipients (career) (Tier 1)
- Congress.gov: Tammy Baldwin member profile (Tier 1)
- Baldwin.senate.gov: FAIR Drug Pricing Act 2021 introduction (Tier 1)
- Baldwin.senate.gov: FAIR Drug Pricing Act passes HELP Committee (2023) (Tier 1)
- Baldwin.senate.gov: Baldwin supports bipartisan INSULIN Act (Tier 1)
- Baldwin.senate.gov: Baldwin celebrates IRA prescription drug pricing (Tier 1)
- Baldwin.senate.gov: Baldwin grills Big Pharma CEOs on drug costs (Tier 1)
- CMS: Medicare Drug Price Negotiation Program (Tier 1)
- CNN: Senate panel grills pharmaceutical CEOs on drug prices (Feb 8, 2024) (Tier 2)
- NPR: Drug company CEOs grilled about high U.S. drug prices (Feb 8, 2024) (Tier 2)
- KFF Health News: Pharma Cash to Congress (Tier 2)
- Ballotpedia: Tammy Baldwin (Tier 3)
content-readiness:: developed